Product Description: Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC50 of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect[1][2].
Applications: Cancer-Kinase/protease
Formula: C22H18FN7
References: [1]Son JY et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis, 2014 Jul, 13(7):1704-16./[2]Naka K, et al. Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells. Cancer Sci. 2016 Feb;107(2):140-8.
CAS Number: 1352608-82-2
Molecular Weight: 399.42
Compound Purity: 99.58
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/Ethanol : 100 mg/mL (ultrasonic)
Target: TGF-β Receptor
Deutsch
English
